Do you want to read an article? Please log in or register.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial
Breast Cancer
RECOMMENDED
Related content
Breast Cancer
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
Lancet Oncol
Brunt AM, Cafferty FH, Kirby AM, Patel J, Sydenham MA, Haviland JS, Griffin S, Chivardi C, Fleming H, Coles CE, Bloomfield DJ, Chan C, Cleator S, Goodman A, Griffin CL, Kirwan CC, Nabi Z, Sawyer E, Somaiah N, Syndikus I, Venables K, Wheatley DA, Yarnold JR, Bliss JM
doi: 10.1016/S1470-2045(26)00076-8
SPECIAL REPORT
Breast Cancer
Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study
Breast Cancer
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial
Eur J Cancer
Wortelboer N, Kent S, Konings IR, van Ommen-Nijhof A, van der Noort V, van den Pol E, Guerrero Páez C, van Bekkum ML, van den Berkmortel FWPJ, Droogendijk HJ, Houtsma D, Oosterkamp HM, van der Padt-Pruijsten A, Siemerink EJM, Tol J, van Zweeden AA, van Leeuwen-Stok AE, Sonke GS, Jager A, Blommestein HM
doi: 10.1016/j.ejca.2025.116051
Breast Cancer
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial
JAMA Oncol
Wang J, Zhang Q, Li H, Tong Z, Ouyang Q, Li H, Teng Y, Wang B, Sun T, Wang J, Li W, Niu Z, Li H, Gong C, Wang S, Wang X, Wu X, Liu N, Yu G, Hu Y, Wang Q, Duan X, Yang F, Wang L, Xu B
doi: 10.1001/jamaoncol.2026.0318
RECOMMENDED
Breast Cancer
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial
★ 2
Recommended by
Dr Andreas Müller, Faculty Member
Lancet Oncol
Saito M, Iihara H, Shimokawa M, Udagawa R, Tsuneizumi M, Futamura M, Ishikawa Y, Ogata H, Bando H, Shima H, Hosoya K, Mukohara T, Tanaka K, Ikuta T, Kawate T, Ishida K, Nakai K, Uomori T, Kutomi G, Ozeki R, Yanagisawa N
doi: 10.1016/S1470-2045(25)00233-5
Breast Cancer
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials
Lancet Oncol
Beshr MS, Fahaid A, Shembesh RH, Valachis A, Lambertini M, Cortesi L, Alesawy AF, Abraheem A, Alsharedi M, Ali ME, Elkhanany A, Azim HA Jr, Velikova G, Elhadi M
doi: 10.1016/S1470-2045(26)00053-7
Breast Cancer
Comparative efficacy and safety of novel oral selective estrogen receptor degraders in ER+/HER2- advanced breast cancer: An updated systematic review and meta-analysis of randomized controlled trials
Cancer Treat Rev
Kirmani N, De León-Fernández N, Rodriguez-Parra JD, Ghanem L, Hakkeem B, Briceño-Morales C, Briceño-Morales X
doi: 10.1016/j.ctrv.2026.103093
RECOMMENDED
Breast Cancer
Metronomic capecitabine as extended adjuvant chemotherapy for early triple-negative breast cancer (SYSUCC-001): updated 10-year outcomes and post-hoc exploratory biomarker analysis from a randomised, phase 3 trial
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet Oncol
Yuan J, Bi XW, Hua X, Huang H, Cai L, Zhao L, Chen QJ, Chen XX, Wang XL, Lin Y, Zhang AQ, Zhong YY, Xu F, Huang JJ, An X, Shi YX, Wang X, Wang SS, Xue C, Yuan ZY
doi: 10.1016/S1470-2045(25)00545-5
RECOMMENDED
Breast Cancer
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial
★ 2
Recommended by
Dr Andreas Müller, Faculty Member
Lancet Oncol
Kirby AM, Finneran L, Griffin CL, Brunt AM, Cafferty FH, Alhasso A, Chan C, Haviland JS, Jefford ML, Sawyer EJ, Sydenham MA, Syndikus I, Tsang YM, Wheatley D, Yarnold JR, Coles CE, Bliss JM
doi: 10.1016/S1470-2045(25)00194-9